Conclusion
A digitoxin dosing score comprising information on age, sex, BMI, and eGFR was derived and validated in patients with HFrEF randomized to digitoxin treatment in the DIGIT-HF trial. The new digitoxin dosing score advises, whether a patient should be started with a low dose of 0.05 mg digitoxin o.d. The digitoxin dosing score can easily be obtained in clinical routine and enables simple and safe initial digitoxin dosing in patients with HFrEF.
Udo Bavendiek and Anika Großhennig contributed equally.